 | • レポートコード：20QY06-08692 • 出版社/出版日：QYResearch / 2020年6月3日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、143ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、良性前立腺肥大症（BPH）薬のグローバル市場について種類別（5α-還元酵素阻害剤、ベータ遮断薬、植物薬、漢方薬）、用途別（病院薬局、小売薬局、オンライン薬局）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・良性前立腺肥大症（BPH）薬市場の概要 ・世界の主要地域別良性前立腺肥大症（BPH）薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の良性前立腺肥大症（BPH）薬市場規模2015-2026：種類別（5α-還元酵素阻害剤、ベータ遮断薬、植物薬、漢方薬） ・世界の良性前立腺肥大症（BPH）薬市場規模2015-2026：用途別（病院薬局、小売薬局、オンライン薬局） ・良性前立腺肥大症（BPH）薬の北米市場規模2015-2020 ・良性前立腺肥大症（BPH）薬のヨーロッパ市場規模2015-2020 ・良性前立腺肥大症（BPH）薬の中国市場規模2015-2020 ・良性前立腺肥大症（BPH）薬の日本市場規模2015-2020 ・良性前立腺肥大症（BPH）薬の東南アジア市場規模2015-2020 ・良性前立腺肥大症（BPH）薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Astellas Pharma、、Eli Lilly、、GlaxoSmithKline、、Sanofi、、ADC Therapeutics、、Bayer HealthCare、、Bristol-Myers Squibb、、Valeant Pharmaceuticals、、Endo Pharmaceuticals、、Foresee Pharmaceuticals、、Merck、、Novartis、、Advaxis、、Teva Pharmaceutical Industries、、Urologixs、、Agennix、、ANI Pharmaceuticals、、BHR Pharma、、Boehringer Ingelheim、、Sanpower Group、、Eisai、、Ferring、、IO THERAPEUTICS、、LIDDS、、Madrigal Pharmaceuticals、、Nymox Pharmaceutical、、Spectrum Pharmaceuticals、、Takeda Pharmaceuticals、） ・良性前立腺肥大症（BPH）薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・良性前立腺肥大症（BPH）薬の市場動向・機会・課題 ・調査の結論 |
A recently published report by QY Research titled Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Benign Prostatic Hyperplasia (BPH) Medication market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
BPH (benign prostatic hyperplasia, BPH) is a common disease and frequently encountered disease in older men, main show is prostate of glands and stroma hyperplasia, prostate enlargement, lower urinary tract symptoms (the lower urinary tract symptom, LUTS), and bladder outlet obstruction.There are currently three major classes of drugs for BPH: 5-beta-reductase inhibitors, such as finasteride;Beta-blockers, such as terazosin hydrochloride, doxazosin mesylate, etc.Herbal preparations and Chinese medicine, such as the general, etc.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Benign Prostatic Hyperplasia (BPH) Medication market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Benign Prostatic Hyperplasia (BPH) Medication industry.
Based on our recent survey, we have several different scenarios about the Benign Prostatic Hyperplasia (BPH) Medication YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Benign Prostatic Hyperplasia (BPH) Medication will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Benign Prostatic Hyperplasia (BPH) Medication market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Benign Prostatic Hyperplasia (BPH) Medication market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Benign Prostatic Hyperplasia (BPH) Medication market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Benign Prostatic Hyperplasia (BPH) Medication market. The report also includes nautical information, where it shows Benign Prostatic Hyperplasia (BPH) Medication market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Benign Prostatic Hyperplasia (BPH) Medication market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Benign Prostatic Hyperplasia (BPH) Medication market.
Geographical Analysis:
Based on region, the global Benign Prostatic Hyperplasia (BPH) Medication market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Benign Prostatic Hyperplasia (BPH) Medication market are
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Merck
Novartis
Advaxis
Teva Pharmaceutical Industries
Urologixs
Agennix
ANI Pharmaceuticals
BHR Pharma
Boehringer Ingelheim
Sanpower Group
Eisai
Ferring
IO THERAPEUTICS
LIDDS
Madrigal Pharmaceuticals
Nymox Pharmaceutical
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Segment by Type
5-Alpha-Reductase Inhibitors
Beta-Blockers
Botanicals and Traditional Chinese Medicine
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Benign Prostatic Hyperplasia (BPH) Medication market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Benign Prostatic Hyperplasia (BPH) Medication market.
• The market share of the global Benign Prostatic Hyperplasia (BPH) Medication market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Benign Prostatic Hyperplasia (BPH) Medication market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Benign Prostatic Hyperplasia (BPH) Medication market.
レポート目次1 Benign Prostatic Hyperplasia (BPH) Medication Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Medication Product Scope
1.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2020-2026)
1.2.2 5-Alpha-Reductase Inhibitors
1.2.3 Beta-Blockers
1.2.4 Botanicals and Traditional Chinese Medicine
1.3 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Comparison by Application (2020-2026)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Forecasts (2015-2026)
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate (2015-2026)
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Growth Rate (2015-2026)
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Benign Prostatic Hyperplasia (BPH) Medication Industry Impact
1.5.1 How the Covid-19 is Affecting the Benign Prostatic Hyperplasia (BPH) Medication Industry
1.5.1.1 Benign Prostatic Hyperplasia (BPH) Medication Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Benign Prostatic Hyperplasia (BPH) Medication Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Benign Prostatic Hyperplasia (BPH) Medication Players to Combat Covid-19 Impact
2 Benign Prostatic Hyperplasia (BPH) Medication Estimate and Forecast by Region
2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2015-2020)
2.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2015-2020)
2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2015-2026)
2.4.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2015-2026)
2.4.3 China Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2015-2026)
2.4.4 Japan Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2015-2026)
2.4.6 India Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2015-2026)
3 Global Benign Prostatic Hyperplasia (BPH) Medication Competition Landscape by Players
3.1 Global Top Benign Prostatic Hyperplasia (BPH) Medication Players by Sales (2015-2020)
3.2 Global Top Benign Prostatic Hyperplasia (BPH) Medication Players by Revenue (2015-2020)
3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Medication as of 2019)
3.4 Global Benign Prostatic Hyperplasia (BPH) Medication Average Price by Company (2015-2020)
3.5 Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Benign Prostatic Hyperplasia (BPH) Medication Players (Opinion Leaders)
4 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Historic Market Review by Type (2015-2020)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2015-2020)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2014-2020)
4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Type (2021-2026)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Type (2021-2026)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price Forecast by Type (2021-2026)
5 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Historic Market Review by Application (2015-2020)
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2015-2020)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2015-2020)
5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Application (2021-2026)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Application (2021-2026)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price Forecast by Application (2021-2026)
3 North America Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
3.2 North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
3.3 North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
3.4 North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
4 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
4.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
4.4 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
5 China Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
5.2 China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
5.3 China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
5.4 China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
6 Japan Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
6.2 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
6.3 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
6.4 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
7 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
7.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
8 India Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
8.2 India Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
8.3 India Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
8.4 India Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Benign Prostatic Hyperplasia (BPH) Medication Business
12.1 Astellas Pharma
12.1.1 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.1.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.1.5 Astellas Pharma Recent Development
12.2 Eli Lilly
12.2.1 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.2.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.2.5 Eli Lilly Recent Development
12.3 GlaxoSmithKline
12.3.1 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.3.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.3.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.3.5 GlaxoSmithKline Recent Development
12.4 Sanofi
12.4.1 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.4.5 Sanofi Recent Development
12.5 ADC Therapeutics
12.5.1 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.5.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.5.4 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.5.5 ADC Therapeutics Recent Development
12.6 Bayer HealthCare
12.6.1 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.6.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.6.5 Bayer HealthCare Recent Development
12.7 Bristol-Myers Squibb
12.7.1 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.7.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.7.5 Bristol-Myers Squibb Recent Development
12.8 Valeant Pharmaceuticals
12.8.1 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.8.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.8.5 Valeant Pharmaceuticals Recent Development
12.9 Endo Pharmaceuticals
12.9.1 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.9.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.9.5 Endo Pharmaceuticals Recent Development
12.10 Foresee Pharmaceuticals
12.10.1 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.10.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.10.5 Foresee Pharmaceuticals Recent Development
12.11 Merck
12.11.1 Merck Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Merck Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.11.5 Merck Recent Development
12.12 Novartis
12.12.1 Novartis Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Novartis Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.12.5 Novartis Recent Development
12.13 Advaxis
12.13.1 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.13.5 Advaxis Recent Development
12.14 Teva Pharmaceutical Industries
12.14.1 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.14.2 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.14.5 Teva Pharmaceutical Industries Recent Development
12.15 Urologixs
12.15.1 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.15.2 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.15.5 Urologixs Recent Development
12.16 Agennix
12.16.1 Agennix Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.16.2 Agennix Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Agennix Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.16.5 Agennix Recent Development
12.17 ANI Pharmaceuticals
12.17.1 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.17.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.17.4 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.17.5 ANI Pharmaceuticals Recent Development
12.18 BHR Pharma
12.18.1 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.18.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.18.4 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.18.5 BHR Pharma Recent Development
12.19 Boehringer Ingelheim
12.19.1 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.19.2 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.19.4 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.19.5 Boehringer Ingelheim Recent Development
12.20 Sanpower Group
12.20.1 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.20.2 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.20.4 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.20.5 Sanpower Group Recent Development
12.21 Eisai
12.21.1 Eisai Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.21.2 Eisai Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.21.4 Eisai Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.21.5 Eisai Recent Development
12.22 Ferring
12.22.1 Ferring Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.22.2 Ferring Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.22.4 Ferring Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.22.5 Ferring Recent Development
12.23 IO THERAPEUTICS
12.23.1 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.23.2 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.23.4 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.23.5 IO THERAPEUTICS Recent Development
12.24 LIDDS
12.24.1 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.24.2 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.24.4 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.24.5 LIDDS Recent Development
12.25 Madrigal Pharmaceuticals
12.25.1 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.25.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.25.4 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.25.5 Madrigal Pharmaceuticals Recent Development
12.26 Nymox Pharmaceutical
12.26.1 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.26.2 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.26.4 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.26.5 Nymox Pharmaceutical Recent Development
12.27 Spectrum Pharmaceuticals
12.27.1 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.27.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.27.4 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.27.5 Spectrum Pharmaceuticals Recent Development
12.28 Takeda Pharmaceuticals
12.28.1 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Corporation Information
12.28.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Business Overview and Total Revenue
12.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2015-2020)
12.28.4 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.28.5 Takeda Pharmaceuticals Recent Development
13 Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Cost Analysis
13.1 Benign Prostatic Hyperplasia (BPH) Medication Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication
13.4 Benign Prostatic Hyperplasia (BPH) Medication Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors List
14.3 Benign Prostatic Hyperplasia (BPH) Medication Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
List of TablesTable 1. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) Growth Rate by Type (2020-2026)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Benign Prostatic Hyperplasia (BPH) Medication Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Benign Prostatic Hyperplasia (BPH) Medication Players to Combat Covid-19 Impact
Table 8. Global Market Benign Prostatic Hyperplasia (BPH) Medication Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Region (2015-2020)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2015-2020)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Region (2015-2020)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) Forecast by Region (2021-2026)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share Forecast by Region (2021-2026)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Medication (KG) of Key Companies (2015-2020)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Company (2015-2020)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Company (2015-2020)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Medication by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Medication as of 2019)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Medication Average Price (USD/KG) of Key Company (2015-2020)
Table 23. Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Sites and Area Served
Table 24. Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Benign Prostatic Hyperplasia (BPH) Medication Players
Table 27. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2015-2020)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Type (2015-2020)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Medication Price (KG) by Type (2015-2020)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Type (2021-2026)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Type (2021-2026)
Table 34. Global Benign Prostatic Hyperplasia (BPH) Medication Price (KG) by Type (2021-2026)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2015-2020)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Application (2015-2020)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Medication Price (KG) by Application (2015-2020)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2021-2026)
Table 40. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Application (2021-2026)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Application (2021-2026)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Medication Price (KG) by Application (2021-2026)
Table 44. United States Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2015-2020)
Table 45. United States Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
Table 46. United States Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2015-2020)
Table 47. United States Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
Table 48. United States Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2015-2020)
Table 49. United States Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2015-2020)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
Table 52. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2015-2020)
Table 53. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
Table 54. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2015-2020)
Table 55. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
Table 56. China Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2015-2020)
Table 57. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
Table 58. China Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2015-2020)
Table 59. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
Table 60. China Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2015-2020)
Table 61. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
Table 62. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2015-2020)
Table 63. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
Table 64. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2015-2020)
Table 65. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
Table 66. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2015-2020)
Table 67. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2015-2020)
Table 69. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2015-2020)
Table 71. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2015-2020)
Table 73. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
Table 74. India Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2015-2020)
Table 75. India Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2015-2020)
Table 76. India Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2015-2020)
Table 77. India Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2015-2020)
Table 78. India Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2015-2020)
Table 79. India Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
Table 80. Astellas Pharma Corporation Information
Table 81. Astellas Pharma Description and Business Overview
Table 82. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 83. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product
Table 84. Astellas Pharma Recent Development
Table 85. Eli Lilly Corporation Information
Table 86. Eli Lilly Description and Business Overview
Table 87. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 88. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product
Table 89. Eli Lilly Recent Development
Table 90. GlaxoSmithKline Corporation Information
Table 91. GlaxoSmithKline Description and Business Overview
Table 92. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 93. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product
Table 94. GlaxoSmithKline Recent Development
Table 95. Sanofi Corporation Information
Table 96. Sanofi Description and Business Overview
Table 97. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 98. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product
Table 99. Sanofi Recent Development
Table 100. ADC Therapeutics Corporation Information
Table 101. ADC Therapeutics Description and Business Overview
Table 102. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 103. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product
Table 104. ADC Therapeutics Recent Development
Table 105. Bayer HealthCare Corporation Information
Table 106. Bayer HealthCare Description and Business Overview
Table 107. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 108. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product
Table 109. Bayer HealthCare Recent Development
Table 110. Bristol-Myers Squibb Corporation Information
Table 111. Bristol-Myers Squibb Description and Business Overview
Table 112. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 113. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product
Table 114. Bristol-Myers Squibb Recent Development
Table 115. Valeant Pharmaceuticals Corporation Information
Table 116. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 117. Valeant Pharmaceuticals Description and Business Overview
Table 118. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 119. Valeant Pharmaceuticals Recent Development
Table 120. Endo Pharmaceuticals Corporation Information
Table 121. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 122. Endo Pharmaceuticals Description and Business Overview
Table 123. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 124. Endo Pharmaceuticals Recent Development
Table 125. Foresee Pharmaceuticals Corporation Information
Table 126. Foresee Pharmaceuticals Description and Business Overview
Table 127. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 128. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 129. Foresee Pharmaceuticals Recent Development
Table 130. Merck Corporation Information
Table 131. Merck Description and Business Overview
Table 132. Merck Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 133. Merck Benign Prostatic Hyperplasia (BPH) Medication Product
Table 134. Merck Recent Development
Table 135. Novartis Corporation Information
Table 136. Novartis Description and Business Overview
Table 137. Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 138. Novartis Benign Prostatic Hyperplasia (BPH) Medication Product
Table 139. Novartis Recent Development
Table 140. Advaxis Corporation Information
Table 141. Advaxis Description and Business Overview
Table 142. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 143. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product
Table 144. Advaxis Recent Development
Table 145. Teva Pharmaceutical Industries Corporation Information
Table 146. Teva Pharmaceutical Industries Description and Business Overview
Table 147. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 148. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product
Table 149. Teva Pharmaceutical Industries Recent Development
Table 150. Urologixs Corporation Information
Table 151. Urologixs Description and Business Overview
Table 152. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 153. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product
Table 154. Urologixs Recent Development
Table 155. Agennix Corporation Information
Table 156. Agennix Description and Business Overview
Table 157. Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 158. Agennix Benign Prostatic Hyperplasia (BPH) Medication Product
Table 159. Agennix Recent Development
Table 160. ANI Pharmaceuticals Corporation Information
Table 161. ANI Pharmaceuticals Description and Business Overview
Table 162. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 163. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 164. ANI Pharmaceuticals Recent Development
Table 165. BHR Pharma Corporation Information
Table 166. BHR Pharma Description and Business Overview
Table 167. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 168. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product
Table 169. BHR Pharma Recent Development
Table 170. Boehringer Ingelheim Corporation Information
Table 171. Boehringer Ingelheim Description and Business Overview
Table 172. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 173. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product
Table 174. Boehringer Ingelheim Recent Development
Table 175. Sanpower Group Corporation Information
Table 176. Sanpower Group Description and Business Overview
Table 177. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 178. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product
Table 179. Sanpower Group Recent Development
Table 180. Eisai Corporation Information
Table 181. Eisai Description and Business Overview
Table 182. Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 183. Eisai Benign Prostatic Hyperplasia (BPH) Medication Product
Table 184. Eisai Recent Development
Table 185. Ferring Corporation Information
Table 186. Ferring Description and Business Overview
Table 187. Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 188. Ferring Benign Prostatic Hyperplasia (BPH) Medication Product
Table 189. Ferring Recent Development
Table 190. IO THERAPEUTICS Corporation Information
Table 191. IO THERAPEUTICS Description and Business Overview
Table 192. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 193. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product
Table 194. IO THERAPEUTICS Recent Development
Table 195. LIDDS Corporation Information
Table 196. LIDDS Description and Business Overview
Table 197. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 198. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product
Table 199. LIDDS Recent Development
Table 200. Madrigal Pharmaceuticals Corporation Information
Table 201. Madrigal Pharmaceuticals Description and Business Overview
Table 202. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 203. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 204. Madrigal Pharmaceuticals Recent Development
Table 205. Nymox Pharmaceutical Corporation Information
Table 206. Nymox Pharmaceutical Description and Business Overview
Table 207. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 208. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product
Table 209. Nymox Pharmaceutical Recent Development
Table 210. Spectrum Pharmaceuticals Corporation Information
Table 211. Spectrum Pharmaceuticals Description and Business Overview
Table 212. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 213. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 214. Spectrum Pharmaceuticals Recent Development
Table . Takeda Pharmaceuticals Corporation Information
Table . Takeda Pharmaceuticals Description and Business Overview
Table . Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table . Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table . Takeda Pharmaceuticals Recent Development
Table 220. Production Base and Market Concentration Rate of Raw Material
Table 221. Key Suppliers of Raw Materials
Table 222. Benign Prostatic Hyperplasia (BPH) Medication Distributors List
Table 223. Benign Prostatic Hyperplasia (BPH) Medication Customers List
Table 224. Market Key Trends
Table 225. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 226. Key Challenges
Table 227. Research Programs/Design for This Report
Table 228. Key Data Information from Secondary Sources
Table 229. Key Data Information from Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Medication Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Benign Prostatic Hyperplasia (BPH) Medication Market Share by Application in 2020 & 2026
Figure 6. Hospital Pharmacies Examples
Figure 7. Retail Pharmacies Examples
Figure 8. Online Pharmacies Examples
Figure 9. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) Growth Rate (2015-2026)
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Medication Price Trends Growth Rate (2015-2026) (USD/KG)
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Benign Prostatic Hyperplasia (BPH) Medication Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) Growth Rate (2015-2026)
Figure 16. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Benign Prostatic Hyperplasia (BPH) Medication Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Benign Prostatic Hyperplasia (BPH) Medication Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Benign Prostatic Hyperplasia (BPH) Medication Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Benign Prostatic Hyperplasia (BPH) Medication Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Benign Prostatic Hyperplasia (BPH) Medication Players Market Share by Revenue in Benign Prostatic Hyperplasia (BPH) Medication 2015 & 2019
Figure 27. Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Type (2015-2020)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Application (2015-2020)
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2019
Figure 33. United States Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2019
Figure 34. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company in 2019
Figure 35. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2019
Figure 36. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application in 2019
Figure 37. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company in 2019
Figure 38. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2019
Figure 39. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application in 2019
Figure 40. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company in 2019
Figure 41. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2019
Figure 42. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application in 2019
Figure 43. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company in 2019
Figure 44. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2019
Figure 45. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application in 2019
Figure 46. India Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company in 2019
Figure 47. India Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2019
Figure 48. India Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application in 2019
Figure 49. Astellas Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. ADC Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Bayer HealthCare Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Valeant Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Endo Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Foresee Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Advaxis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Teva Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Urologixs Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Agennix Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. ANI Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. BHR Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Sanpower Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. Eisai Total Revenue (US$ Million): 2019 Compared with 2018
Figure 70. Ferring Total Revenue (US$ Million): 2019 Compared with 2018
Figure 71. IO THERAPEUTICS Total Revenue (US$ Million): 2019 Compared with 2018
Figure 72. LIDDS Total Revenue (US$ Million): 2019 Compared with 2018
Figure 73. Madrigal Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 74. Nymox Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 75. Spectrum Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 76. Takeda Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 77. Key Raw Materials Price Trend
Figure 78. Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Medication
Figure 79. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication
Figure 80. Benign Prostatic Hyperplasia (BPH) Medication Industrial Chain Analysis
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Porter's Five Forces Analysis
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
良性前立腺肥大治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Benign Prostatic Hyperplasia Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.3% in the forecast period of 2020 to 2025 and will expected to reach USD 7532.5 million by 2025, from USD 6626.4 million in 2019…- にきび薬の世界市場レポート2020 Acne medications are drugs that are indicated for the treatment of acne. Market Analysis and Insights: Global Acne Medication Market The global Acne Medication market was valued at US$ 6898.4 million in 2019 and will reach US$ 8053.8 million by the end of 2026, growing at a CAGR of 2.2% during 2020-…
- にきび用薬品の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Acne Medication market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.1% in the forecast period of 2020 to 2025 and will expected to reach USD 7718.3 million by 2025, from USD 7098.1 million in 2019. The Acne Medication mark…
- 過活動膀胱薬の世界市場レポート2020 A recently published report by QY Research titled Global Overactive Bladder Medication Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provid…
- 投薬遠隔管理デバイスの世界市場レポート2020 Market Analysis and Insights: Global Medication Telemanagement Devices Market The global Medication Telemanagement Devices market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Medication Telemanagement Devices…